Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania

BMC Public Health. 2008 Dec 19:8:416. doi: 10.1186/1471-2458-8-416.

Abstract

Background: Tanzania is currently scaling-up access to anti-retro viral therapy (ART) to reach as many eligible persons as possible. Hepatitis viral co-infections are known to influence progression, management as well as outcome of HIV infection. However, information is scarce regarding the prevalence and predictors of viral hepatitis co-infection among HIV-infected individuals presenting at the HIV care and treatment clinics in the country.

Methods: A cross-sectional study conducted between April and September 2006 enrolled 260 HIV-1 infected, HAART naïve patients aged > or = 18 years presenting at the HIV care and treatment clinic (CTC) of the Muhimbili National Hospital (MNH). The evaluation included clinical assessment and determination of CD4+ T-lymphocyte count, serum transaminases and serology for Hepatitis A, B and C markers by ELISA.

Results: The prevalence of anti HAV IgM, HBsAg, anti-HBc IgM and anti-HCV IgG antibodies were 3.1%, 17.3%, 2.3% and 18.1%, respectively. Dual co-infection with HBV and HCV occurred in 10 individuals (3.9%), while that of HAV and HBV was detected in two subjects (0.8%). None of the patients had all the three hepatitis viruses. Most patients (81.1%) with hepatitis co-infection neither had specific clinical features nor raised serum transaminases. History of blood transfusion and jaundice were independent predictors for HBsAg and anti-HBc IgM positivity, respectively.

Conclusion: There is high prevalence of markers for hepatitis B and C infections among HIV infected patients seeking care and treatment at MNH. Clinical features and a raise in serum alanine aminotransferase were of limited predictive values for the viral co-infections. Efforts to scale up HAART should also address co-infections with Hepatitis B and C viruses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / blood
  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / epidemiology*
  • Adolescent
  • Adult
  • Antiretroviral Therapy, Highly Active
  • Biomarkers
  • Comorbidity
  • Cross-Sectional Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hepatitis A / blood
  • Hepatitis A / complications
  • Hepatitis A / epidemiology*
  • Hepatitis Antibodies / blood*
  • Hepatitis Antibodies / classification
  • Hepatitis B / blood
  • Hepatitis B / complications
  • Hepatitis B / epidemiology*
  • Hepatitis B Antibodies / blood
  • Hepatitis B Surface Antigens / blood
  • Hepatitis C / blood
  • Hepatitis C / complications
  • Hepatitis C / epidemiology*
  • Humans
  • Male
  • Middle Aged
  • Outpatient Clinics, Hospital / statistics & numerical data*
  • Risk Factors
  • Seroepidemiologic Studies
  • Tanzania / epidemiology
  • Young Adult

Substances

  • Biomarkers
  • Hepatitis Antibodies
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens